The patient’s CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide

R Crocchiolo,L Castagna, S Furst,R Devillier,B Sarina,S Bramanti,J El-Cheikh, A Granata, S Harbi, L Morabito,C Faucher,A Rimondo, D Girardi, B Mohty,B Calmels,C Carlo-Stella, C Chabannon,R Bouabdallah, A Santoro,N Vey,P J Weiller,D Blaise

BONE MARROW TRANSPLANTATION(2016)

引用 28|浏览29
暂无评分
摘要
The patient’s CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide
更多
查看译文
关键词
cmv,cyclophosphamide,clinical outcome,serological status,t-cell,haplo-hsct,post-transplant
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要